Ireland· IE-PA-EU/1/25/2003/001-006
Inluriyo 200 mg film-coated tablets
A anti-estrogens product containing imlunestrant tosilate, registered in Ireland by Eli Lilly and Company Limited. The same ATC class is registered in 5 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Imlunestrant tosilate is registered in 5 of 19 countries.
Countries holding a registration under ATC L02BA (anti-estrogens), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 3 of them publish a price we can compare per daily dose
Imlunestrant tosilate · ATC L02BA
5 / 19 countries
- Czechiaprice
- Denmark
- Icelandprice
- Ireland
- Switzerlandprice
The record
At a glance
HPRA (Ireland)- Active substance
- Imlunestrant tosilate
- Manufacturer
- Eli Lilly and Company Limited
- Country
- Ireland (IE)
- ATC code
- L02BA
- ATC class
- Anti-estrogens
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/25/2003/001-006
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Imlunestrant tosilate in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaINLURIYOEli Lilly Nederland B.V., Utrecht
- SwitzerlandInluriyo 200 mg, comprimés pelliculésEli Lilly (Suisse) SA
- United StatesInluriyoEli Lilly and Company
- BelgiumInluriyo 200 mgEli Lilly Nederland
- NetherlandsInluriyo 200 mg filmomhulde tablettenEli Lilly Nederland B.V.
- PolandInluriyoEli Lilly Nederland B.V.
- SwedenInluriyo 200 mg Filmdragerad tablettEli Lilly Nederland B.V.
- IcelandInluriyoEli Lilly Nederland B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Inluriyo
- Liechtenstein · Inluriyo
- Norway · Inluriyo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/16a75a43-3339-4e77-a9e2-e8620915e4b3 GET /v1/drugs/16a75a43-3339-4e77-a9e2-e8620915e4b3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L02BA"
],
"strength": null,
"pa_number": "EU/1/25/2003/001-006",
"substances": [
"Imlunestrant tosilate"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "09/01/2026",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about imlunestrant tosilate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.